摘要
目的采用系列行为学评价手段评测梓醇对局灶脑缺血大鼠神经功能恢复的影响,探讨其治疗时间窗和有效治疗剂量。方法制备局灶永久性脑缺血大鼠模型,于造模后6h、24 h两个时点开始腹腔注射给予低、中、高剂量(1、5、10mg.kg-1)梓醇进行治疗,每日1次,连续7 d,分别于造模后1、4、7、15、21 d,进行Bederson评分、肌力评定、平衡木行走试验、受累前肢食物抓取成功率测试。结果与模型组比较,各种神经行为学评价梓醇治疗组均有改善;其中术后21d,梓醇中、高剂量组受累前肢(左)食物抓取成功率分别为48.7%±5.4%(约相当于基线值72%)和47.3%±4.8%(约相当于基线值70%),与模型组(25.8%±4.1%,约相当于基线值38%)比较差异具有显著性(P<0.05)。提示梓醇对脑缺血后感觉运动功能恢复有促进作用。但术后21 d,术后6 h给药组和术后24 h给药组左前肢食物抓取成功率差异无显著性(P>0.05),提示脑缺血后延迟给予梓醇治疗仍对大鼠神经功能恢复有促进作用。结论采用Bederson评分、肌力评定、平衡木行走试验和左前肢食物抓取功能测定等多种方法,证实梓醇对脑缺血后功能恢复有促进作用,后两种评价方法更为灵敏;梓醇治疗有效剂量为1～10 mg.kg-1,缺血后24 h给药仍然有效。
Aim To research time window and dose treatment with catalpol through obseversion and evalua- tion of a neurologic function recovery in rat after permanent middle cerebral artery occlusion （p-MCAO）. Methods Eight groups were designed as sham-operated, model, ischemia-treated with catalpol, Citicoline and saline respectively. Catalpol was injected intraperitoneally 6h and 24h after pMCAO and repeatedly each day for7d with the doses of 1,5,10 mg· kg^-1. The neuroprotection was estimated by the indexes of behavior： the effects of catalpol on pMCAO rats was per- formed in a battery behavioral testing（ Bederson scores, muscle strength scores, Beam walking scores and affected forelimb skilled reaching test ） at different time points of 1, 4, 7, 14, 21 d after pMCAO. Results Bederson score, balance function, muscle strength andpercent success on forelimb skilled reaching were＇improved at most time points after the operation. Especially the percent success on forelimb skilled reaching in catalpol group was 48.7% ± 5.4% and 47.3% ± 4. 8% at doses of 5 and 10 mg · kg^-1 respectively, it was increased significantly than that of control group and model group （P 〈 0. 05 ）. It showed that catalpol could contribute to functional recovery of nerves after pMCAO. Conclusion Catalpol （ 1,5,10 mg · kg^-1 ） improves SD rats neurobehavioral consequences after pMCAO is evaluated by a battery of behavioral tests. 24 h after stroke, it is still effective to give catalpol at the dose of 5 mg ·kg^-1 .
出处
《中国药理学通报》
CAS
CSCD
北大核心
2012年第9期1208-1214,共7页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81073084)
重庆市自然科学基金资助项目(No CSTC
2010BB5127)
教育部中央高校重点项目资助项目(No XDJK2012B010)
作者简介
万东（1971-），男，博士，主治医师，研究方向：脑血管疾病及新药研发，Tel：023-89012670，E-mail：wd8866@yahoo．com；
谢鹏（1958-），男，教授，博士生导师，通讯作者，Tel：023-68485490，Fax：023-68485111；E-mail：XieP1958@yahoo．com．cn
